A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers

Paul M Karpecki,1,2 Sidney L Weiss,3 William G Kramer,4 Patrick O’Connor,5 David Evans,6 Josh Johnston,7 April L Jasper,8 Angela Justice,9 Abayomi B Ogundele,9 Doug Devries10 1Kentucky Eye Institute, Lexington, KY, USA; 2Gaddie Eye Centers, Louisville, KY, USA; 3i-novion, Inc., Randolph, NJ,...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Karpecki PM, Weiss SL, Kramer WG, O'Connor P, Evans D, Johnston J, Jasper AL, Justice A, Ogundele AB, Devries D
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Dove Medical Press 2019-04-01
Rangatū:	Clinical Ophthalmology
Ngā marau:	dry eye disease cyclosporine pharmacokinetic systemic exposure
Urunga tuihono:	https://www.dovepress.com/a-phase-1-open-label-single-arm-study-evaluating-the-ocular-safety-of--peer-reviewed-article-OPTH
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!